● Recruiting

Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Condition: Behcet Syndrome, Intestinal Type · Sponsor: Peking Union Medical College Hospital

PhasePhase 2

Planned participants56

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence， alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.

This description comes directly from the study's public registry record.

Talk to the study team

Jinjing Liu, M.D. · 86-10-69151188 · pumch_followup@126.com

Wenjie Zheng, M.D.

Always discuss trial participation with your own doctor first.

Locations (2)

Peking Union Medical College Hospital	Beijing, Beijing Municipality, China	Not Yet Recruiting
Peking Union Medical College Hospital	Beijing, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06849908